Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
331.5 CHF | -0.15% | -0.30% | +9.41% |
Apr. 16 | Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization | MT |
Apr. 12 | Dental Equipment Company Straumann Names New Chair | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.59 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.41% | 4.99B | B- | ||
-5.51% | 182B | C+ | ||
+2.33% | 111B | C | ||
-3.62% | 68.48B | A | ||
+1.52% | 49.69B | B- | ||
+8.06% | 44.46B | B- | ||
+6.38% | 40.67B | B+ | ||
+23.35% | 31.22B | B | ||
+0.67% | 26.09B | A- | ||
+18.48% | 25.32B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- YPSN Stock
- Ratings Ypsomed Holding AG